Navigation Links
Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India
Date:10/23/2007

w.thermofisher.com .

The following constitutes a "SafeHarbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our Website under the heading "SEC Filings." We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental r
'/>"/>

SOURCE Thermo Fisher Scientific Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bronchial thermoplasty – a promising treatment for asthmatic
2. Menthol Receptor-A Thermosensitivity Determinant in Cold Temperature
3. Bronchial Thermoplasty: Boon to Severe Asthma Patients?
4. Scientific markers of aging described
5. A Settlement Over Stem Cell Controversy Through Scientific Research
6. A Scientific Explanation For Out Of Body Experience
7. PUFA Good For Heart: Gets The Scientific Seal
8. Forensic Phonetics – Scientific Solution for Legal Problem
9. Old Indian Advice Has A Scientific Backing Now!
10. India To Highlight Its Scientific Achievements
11. Thumbs up in weight loss for vegetarian diets: scientific review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... PA (PRWEB) July 29, 2014 ... the Sewickley and Moon Township areas, has affiliated with ... Women’s Health will continue to deliver babies and perform ... need of advanced care will be referred to Allegheny ... are proud to be associated with West Penn Hospital ...
(Date:7/29/2014)... Representatives with BNatrl announced today that ... BNatrl Silver Solution 12ppm . , “It’s safe for ... BNatrl LLC. “It helps boost your immune system and ... and microbes.” , BNatrl develops and manufactures organic food ... 10 percent of profits being used to fund projects ...
(Date:7/29/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... According to the new market research report, "Fingerprint ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... & Finance), and Geography - Global Trends & ... the global Fingerprint Sensors Market is projected to ... high CAGR of 16.8% from 2014 to 2020. ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma ... Edition) not only provided a comprehensive and thorough knowledge ... imported drug registration but also introduced the practical operation ... you to use the Chinese trial venues to keep ... step by step. , The audiences of this guidebook ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- Some ... unexplained breathing problems that may be related to exposure ... disorders are emerging as a major consequence of service ... King, an assistant professor of pulmonary and critical care ...
... By Maureen Salamon HealthDay Reporter , ... both cause red, scaly skin rashes, but the similarities ... And now, examining patients suffering from both ... out the opposing immune system responses that prompt skin ...
... scientists have developed a gene-based test to distinguish harmless ... help some patients avoid needless surgery to remove the ... published in the July 20 issue of Science ... cysts are identified in more than a million patients ...
... July 20 (HealthDay News) -- The number of surgical errors ... study finds. In reviewing adverse events and close calls ... in the July 15 issue of the Archives of ... greater emphasis on safety, as well as improved training and ...
... Nev. Caffeine reduces muscle activity in the Fallopian tubes ... "Our experiments were conducted in mice, but this finding goes ... reduce a woman,s chance of becoming pregnant," says Sean Ward, ... Nevada School of Medicine, who conducted the study. ...
... The American Society for Radiation Oncology (ASTRO) has ... Junior Faculty Career Research Training Award and the ... Winners were selected by ASTRO,s Research Evaluation Committee. ... is awarded to stimulate interest in radiation research ...
Cached Medicine News:Health News:Breathing Problems Strike Soldiers Returning From Iraq 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 3Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:Fewer Surgical Errors Reported at VA Medical Facilities 2Health News:Nevada School of Medicine researcher finds caffeine consumption, female infertility link 2
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... , July 29, 2014  Based on ... systems (PERS) market, Frost & Sullivan recognizes MobileHelp ... Award for Price Performance Value Leadership. MobileHelp,s leadership ... captures expectations for tech progression in personal emergency ... for these solutions. MobileHelp is at ...
(Date:7/29/2014)... Medical Corporation (Apex, TWSE: 4106), a leading player in the ... is appealing the judgment of the Regional Court of ... that found the headgear of certain mask models infringe a ... against various ResMed patents in major countries. Apex further reiterates ... ResMed filed the lawsuit with the Regional ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Apex Continues Fighting Against Patents to Free Up Competition 2
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used for temporary suprapubic urinary diversion ... puncture the bladder. The access sheath is ... Once the catheter is introduced, the access ... low-profile catheter support is included for external ...
... and a FAM-labeled probe targeting the VP1 gene ... ASR contains primers and a Texas Red-labeled probe ... an instrument that can detect FAM and Texas ... Analyte Specific Reagent* (ASR) program is comprised of ...
Medicine Products: